Feedback / Questions
VBS102 - Ollin Biosciences
https://www.prnewswire.com/news-releases/velavigo-announces-second-out-licensing-deal-of-a-first-in-class-bi-specific-antibody-further-validating-its-innovative-discovery-platform-and-sustainable-bdvc-business-model-302431714.html
Apr 17, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next